Gelesis is a biotherapeutics company advancing a novel hydrogel platform technology to treat obesity, help with weight management, and other chronic metabolic diseases.

Register for Details

For more details on financing and valuation for Gelesis, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

What is Gelesis's ticker symbol?

GLS

What is Gelesis's stock price?

0.18 as of 3/27/23

Gelesis Funding Rounds and IPO Valuation

Date Funding Round Funding Raised Price per Share IPO Valuation
7/19/2020 Series Growth 3 $801MM $XXX.XX $XXX.XX
2/28/2018 Series Growth 2 $215.68MM $XXX.XX $XXX.XX
12/30/2015 Series Growth $181.84MM $XXX.XX $XXX.XX
3/26/2015 Series A-5 $147.36MM $XXX.XX $XXX.XX
5/16/2014 Series A-4 $33.3MM $XXX.XX $XXX.XX
1/3/2008 Series A-1, A-2, and A-3 $21.45MM $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data

Learn more about Gelesis

Forge green plus iconForge green minus icon

What is Gelesis funding to date?

Gelesis has raised $207.14MM with the following series:
$21.45MM for Series A-1, A-2, and A-3, $33.3MM for Series A-4, $147.36MM for Series A-5, $181.84MM for Series Growth, $215.68MM for Series Growth 2, $801MM for Series Growth 3, $21.45MM for Series A-1, A-2, and A-3, $33.3MM for Series A-4, $147.36MM for Series A-5, $181.84MM for Series Growth, $215.68MM for Series Growth 2, $801MM for Series Growth 3.
Forge green plus iconForge green minus icon

When was Gelesis founded?

Gelesis was founded in 2006.